Business Wire

First Set of Recommendations Advocating for the Holistic Care of People Living with hATTR Amyloidosis Developed by International Panel of Patient Advocates and Healthcare Professionals


Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the first-ever recommendations for patient- and family-centred holistic care for people living with hereditary transthyretin-mediated amyloidosis, also known as hATTR or ATTRv*. The recommendations, published in the BMJ Open,1 were developed by an expert panel of patient advocates and healthcare professionals (HCPs), the Primary Consensus Panel, and endorsed by an International Delphi Survey. They are the first to recognise the value of the patient community in advocating for the needs of people affected by this rare disease and call for a major shift in the current approach to its management.

Within the recommendations, the panel calls for early diagnosis, treatment initiation, and coordinated multidisciplinary care, as well as open dialogue between HCPs and patients to support shared decision-making and consistent monitoring of disease progression. The recommendations also highlight the importance of a tailored family-centred care plan inclusive of supportive care to enable patients to preserve their independence and quality of life.

“hATTR amyloidosis is an inherited, progressively debilitating, and often fatal multisystem disease. Its complexity and severity mean every aspect of a person’s life is affected,” said Dr. Laura Obici, Primary Consensus Panel Co-Chair and Internist at the Amyloidosis Research and Treatment Center, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy. “These recommendations provide healthcare professionals with a new blueprint for care that can potentially have a significant impact on a patient's quality of life. We must start to think beyond treating a patient’s symptoms to other allied healthcare services that can help with the physical, psychological, social, and spiritual aspects of living with this disease.”

With support from Alnylam, the panel developed 50 recommendations that were tested via a robust International Delphi Survey of 122 HCPs and patient advocacy group representatives from 27 countries. The international HCP-patient advocacy community endorsed 98% of the recommendations, which focussed on seven core areas aimed to improve patient care: early diagnosis and access to treatment, disease monitoring and organisation of care, maintenance of physical and mental health, family-centred care and caregiver support, patient-HCP dialogue and shared decision-making, access to community social support, and spiritual support and social networking.

“The outlook for those in my family with hATTR amyloidosis who went before me, including my aunt, cousin, and father, used to be hopeless and dire. I am so proud to have contributed to the development of these recommendations so that they reflect not only my experience as someone living with the condition, but those of the broader patient community,” said Rosaline Callaghan, Primary Consensus Panel Co-Chair and founder of Amyloidosis Ireland, the patient advocacy group for the 32 counties of Ireland. “These recommendations underscore the importance of more robust holistic care plans to bring us one step closer to ensuring people living with hATTR amyloidosis are empowered to live life to the fullest.”

In addition to testing the level of agreement for each recommendation, the survey asked voters to assess the current degree of implementation of each recommendation in their institution or practice. Most HCPs considered certain recommendations on early diagnosis and intervention, genetic counselling and testing, nutritional support, and tailored care provided at specialist centres to be part of standard practice. However, the majority of recommendations were considered achievable with currently available resources, and many were assessed to be attainable only with further funding and reorganisation of care. The findings highlight the need for further discussion and guidance on how to develop services to address the complex needs of those affected by this rare disease.

“We welcome the publication of these recommendations that offer a roadmap for supporting people affected by hATTR amyloidosis, including their families and carers,” said Claudia Cravesana, Interim Head of International Medical Affairs, Alnylam. “Collaboration from all parts of the community will be key to further improve clinical practice. Alnylam is fully committed to supporting these efforts and working with healthcare professionals and patient advocates to accelerate a more holistic approach to patient care.”

This study, and its resultant presentations and publications, were funded by Alnylam Pharmaceuticals. Medical writing support was provided by Lumanity, a medical communications agency.

*Variant transthyretin amyloidosis (ATTRv) is an autosomal dominant inherited disease, where the mutation of the transthyretin gene (TTR) results in the deposition of pathogenic protein fibrils in various tissues.2

About the Primary Consensus Panel, Recommendations, and Methodology

The Primary Consensus Panel is a joint patient and healthcare professional collaborative forum, established in 2020 to develop these consensus recommendations and advocate for improved standards of holistic care in hATTR amyloidosis. The panel consists of 14 multidisciplinary members from eight countries representative of patients, patient advocacy groups (PAGs), key clinical specialties (neurology, cardiology, physiotherapy, psychology, nutrition, and nursing), and industry (Alnylam).

The aims of the recommendations were to: minimise delays in diagnosis and treatment initiation in symptomatic patients; promote collaborative and coordinated multidisciplinary care; ensure tailored support according to the needs of each patient; advocate for family-centred care and caregiver support; foster an open and honest dialogue to support shared decision-making; help patients preserve independence through maintenance of physical health and financial and social support; and encourage community programmes for patients and families to promote acceptance, build resilience and support well-being.

A modified Delphi methodology which included the following three steps was used for this study: (1) formation of a Primary Consensus Panel for the origination and agreement of draft recommendations using anonymised online voting (Voting round 1); (2) anonymised online voting on translated draft recommendations from the wider international clinical and advocacy community (Voting round 2); (3) discussion and modification of recommendations by Primary Consensus Panel for final vote by the international panel if consensus was not reached (Voting round 3). The aim was to achieve consensus on recommendations for the holistic care of people with hATTR amyloidosis.3

About hATTR Amyloidosis

Hereditary transthyretin-mediated (hATTR) amyloidosis is an inherited, progressively debilitating, and fatal disease caused by variants (i.e., mutations) in the TTR gene. TTR protein is primarily produced in the liver and is normally a carrier of vitamin A and thyroxin. Variants in the TTR gene cause abnormal amyloid proteins to accumulate and damage body organs and tissue, such as the peripheral nerves and heart, resulting in intractable peripheral sensory-motor neuropathy, autonomic neuropathy, and/or cardiomyopathy, as well as other disease manifestations. hATTR amyloidosis represents a major unmet medical need with significant morbidity and mortality affecting approximately 50,000 people worldwide. The median survival is 4.7 years following diagnosis, with a reduced survival (3.4 years) for patients presenting with cardiomyopathy.

About Alnylam Pharmaceuticals

Alnylam is a biopharma company leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam is headquartered in Cambridge, MA.

1 Obici L, Callaghan R, Ablett J, et al. Consensus Recommendations on Holistic Care in Hereditary ATTR Amyloidosis: An International Delphi Survey of Patient Advocates and Multidisciplinary Healthcare Professionals. BMJ Open 2023;0:e073130. doi:10.1136/bmjopen-2023-073130
2 Pozsonyi, Z. et al. Variant Transthyretin Amyloidosis (ATTRv) in Hungary: First Data on Epidemiology and Clinical Features. Genes. 2021; 8:1152
3 Niederberger M, et al. Delphi Technique in Health Sciences: A Map. Frontiers in Public Health. 2020; 8:457

To view this piece of content from, please give your consent at the top of this page.

Contact information

Alnylam Pharmaceuticals, Inc.

Emily Bunting
(Media, Europe)
+41 79 866 97 03

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FRESOR's Big Breakthrough Shakes Up the European Vaping Industry28.9.2023 10:00:00 EEST | Press release

FRESOR, as the world's Leading Vaping Technology Platform, launched upgraded FRESOR NOVA technology and its latest product, FRESOR Slim at InterTabac 2023. This marks its first-ever launch in Germany and the third foray into the European market this year, following its successful debuts at Vaper Expo UK 2023 in Birmingham, UK, and Vapitaly 2023 in Italy in May. The exhibition achieved tremendous success, leaving a lasting impression on all attendees. This press release features multimedia. View the full release here: (Photo: Business Wire) "Where Flavor Meets Technology" On the opening day of the exhibition, September 14th, FRESOR hosted a spectacular product launch event at booth 3.F50, themed "Where Flavor Meets Technology." 1. Upgraded FRESOR NOVA technology During this event, FRESOR proudly unveiled its flagship offering – Upgraded FRESOR NOVA technology. This cutting-edge technology is specifically designed for small-capaci

AI Alignment Lab Achieves Major Milestone in Step Towards Agentic AI28.9.2023 08:00:00 EEST | Press release

Aligned AI, a leader in artificial intelligence (AI) research, has announced a groundbreaking AI advancement in misgeneralization, a critical challenge in the field of AI. It is the first to surpass a key benchmark called CoinRun by teaching an AI to “think” in human-like concepts. The technology underpinning the achievement opens the door to more precise, reliable, and controllable AI for a wide variety of real world applications. By teaching AI models to generalize in a manner more akin to agentic human cognition, Aligned AI’s innovation enables AI to correctly identify concepts across new situations and environments, reducing the need for prolonged production, testing, and retraining. Misgeneralization occurs when AI systems learn incorrect patterns and behaviors from their training data, and are not able to correctly adapt when presented with new information. This leads to unexpected, and often harmful, outcomes. Today’s foundation models suffer from varying degrees of misgeneraliz

Interactive Brokers Group Consolidates EU Operations into Ireland28.9.2023 07:00:00 EEST | Press release

Interactive Brokers Group (Nasdaq: IBKR), a leading global brokerage firm, today announced the consolidation of its European brokerage operations, with Interactive Brokers Central Europe (“IBCE”), based in Budapest Hungary, merging its client base and operations into the operations of Interactive Brokers Ireland (“IBIE”). The Group expects the merger of its European operations to produce measurable improvements in efficiency, while retaining its key talent pool and regional client focus. IB Ireland, based in Dublin and regulated by the Central Bank of Ireland, will manage the merged business, with IBCE continuing to provide its expertise to clients across the continent, and particularly in Central and Eastern Europe. Since commencing business following Brexit, these two operations have delivered and supported significant client growth as Interactive Brokers Group expands its presence across Europe. "This decision is consistent with the Group’s continuous focus on operational efficiency

TSMC Announces Breakthrough Set to Redefine the Future of 3D IC27.9.2023 22:17:00 EEST | Press release

TSMC (TSE: 2330, NYSE: TSM) today announced the new 3Dblox 2.0 open standard and major achievements of its Open Innovation Platform® (OIP) 3DFabric Alliance at the TSMC 2023 OIP Ecosystem Forum. The 3Dblox 2.0 features early 3D IC design capability that aims to significantly boost design efficiency, while the 3DFabric Alliance continues to drive memory, substrate, testing, manufacturing, and packaging integration. TSMC continues to push the envelope of 3D IC innovation, making its comprehensive 3D silicon stacking and advanced packaging technologies more accessible to every customer. “As the industry shifted toward embracing 3D IC and system-level innovation, the need for industry-wide collaboration has become even more essential than it was when we launched OIP 15 years ago,” said Dr. L.C. Lu, TSMC fellow and vice president of Design and Technology Platform. “As our sustained collaboration with OIP ecosystem partners continues to flourish, we’re enabling customers to harness TSMC’s le

Linksys Announces the Next Step in Home and Small Office Network Security27.9.2023 20:00:00 EEST | Press release

Linksys®, an iconic Home and Small Office connectivity company, announces in a statement of direction the new Cognitive™ Security capability, which will complement the newly released Designer Series through the end of the year. Cognitive Security technology will then be released in the soon-to-be announced Icon Series later this year. This press release features multimedia. View the full release here: Image of one white WiFi node, one grey WiFi node and one black WiFi node placed in a zig-zag formation (Photo: Business Wire) Designer Series products that will feature Cognitive Security are: Velop® Pro 6E – currently shipping Velop Pro 7 – shipping in September Velop Micro Router 6 – expected in October/November Velop Micro Mesh 6 – expected in October/November The term “Cognitive” in the technology space refers to “thinking technologies,” which can deterministically, either by user selection or automation, solve problems. In Pha

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom